Rhythm

Eko Collaborates with Mayo Clinic on a Machine Learning-Based Algorithm to Help Physicians Better Screen for Potentially Dangerous Heart Diseases

Berkeley, CA, Oct. 25, 2018 (GLOBE NEWSWIRE) — Eko, creators of a heart and lung monitoring platform that combines non-invasive cardiac sensors with machine learning, has announced a collaboration with Mayo Clinic to develop a data-driven technology – using machine learning and a smart digital stethoscope – to help physicians detect […]

AtriCure to Participate in Upcoming Investor Conferences

MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will be participating in upcoming investor conferences. AtriCure is scheduled to present at the Stifel 2018 Healthcare Conference in New York City on Wednesday, […]

Biotricity Extends Heart Rate Variability Research to Include Fetal and Maternal Applications

REDWOOD CITY, Calif., Oct. 23, 2018 (GLOBE NEWSWIRE) — Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, today announced that it will be expanding the scope of a previously approved clinical investigation of fetal heart rate variability (fHRV) to include maternal HRV and other key physiologic metrics […]

Correvio Announces Intention to Re-File Brinavess® NDA in Second Quarter 2019

VANCOUVER, Oct. 23, 2018 /PRNewswire/ – Correvio Pharma Corp. (NASDAQ: CORV /TSX: CORV), a specialty pharmaceutical company focused on providing high-quality brands to acute care physicians and patients, today announced that, based on productive pre-NDA discussions with the U.S. Food and Drug Administration (FDA), Correvio plans to resubmit the Brinavess® […]

ABBOTT’S HEARTMATE 3 HEART PUMP NOW FDA APPROVED FOR ADVANCED HEART FAILURE PATIENTS NOT ELIGIBLE FOR A HEART TRANSPLANT

ABBOTT PARK, Ill., Oct. 19, 2018 /PRNewswire/ — Abbott (NYSE: ABT) announced today that the HeartMate 3™ Left Ventricular Assist Device (LVAD) has received U.S. Food and Drug Administration (FDA) approval as a destination therapy for people living with advanced heart failure. With the approval, physicians can now offer the HeartMate 3 system to patients not […]

Bardy Diagnostics™ awarded Innovative Technology Contract with Vizient, Inc. for the Carnation Ambulatory Monitor™

SEATTLE, Oct. 11, 2018 /PRNewswire/ — Bardy Diagnostics, Inc., (“BardyDx”), a leading provider of ambulatory cardiac monitoring technologies and custom data solutions, announced today it was awarded an Innovative Technology contract with Vizient, Inc. for the Carnation Ambulatory Monitor (“CAM™”), the world’s first P-wave centric™ ambulatory cardiac patch monitor and arrhythmia […]

Geneva Health Solutions Launches Geneva University

NEW YORK–(BUSINESS WIRE)–Geneva Health Solutions (GHS), the leading cloud-based technology platform and service for managing data from implantable cardiac devices, has formalized its internal training systems by launching Geneva University, a business unit within GHS. Geneva University will be focused on the continuous improvement of all clinical and administrative processes. “Implantable […]

Heart Center Dresden to Be First Commercial Clinical Site for Imricor

MINNEAPOLIS–(BUSINESS WIRE)–Imricor announced today that it signed its first commercialization contract for the Advantage-MR EP Recorder/Stimulator System and supporting Vision-MR devices1 with the Heart Center Dresden in Germany. This agreement places the Heart Center Dresden at the forefront of clinical advancement for MRI-guided cardiac ablations and establishes the hospital as a […]

Adagio Medical Completes Chronic Pre-Clinical Atrial Fibrillation Study Using Ultra-Low Temperature Cryoablation Technology

LAGUNA HILLS, Calif., Oct. 4, 2018 /PRNewswire/ — Adagio Medical, Inc., the developer of the iCLAS™ technology, the company’s ultra-low temperature intelligent continuous lesion ablation system for the treatment of cardiac arrhythmias, announces the successful completion of its chronic atrial fibrillation animal study, performed in collaboration with the LIRYC Research Institute of Bordeaux, […]

EPIX Therapeutics Announces Completion of DIAMOND-AF Paroxysmal Study and First Enrollment in DIAMOND-AF II Persistent Study

SANTA CLARA, Calif., Oct. 4, 2018 /PRNewswire/ — EPIX Therapeutics, Inc., a medical device company that designs and manufactures a catheter-based system for the treatment of patients with atrial fibrillation (AFIB), today announced achievement of the enrollment goal of the DIAMOND-AF study, a global FDA-approved IDE pivotal study to evaluate the DiamondTemp Ablation […]